Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP)’s share price rose 6.5% during trading on Wednesday . The stock traded as high as $1.98 and last traded at $1.98. Approximately 1,396,300 shares changed hands during mid-day trading, an increase of 29% from the average daily volume of 1,079,000 shares. The stock had previously closed at $1.86.
OHRP has been the topic of several recent analyst reports. Roth Capital initiated coverage on Ohr Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research raised Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Wednesday, October 18th. Finally, ValuEngine raised Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.
The company has a market cap of $114.64, a price-to-earnings ratio of -3.36 and a beta of 0.48.
COPYRIGHT VIOLATION NOTICE: This report was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.chaffeybreeze.com/2018/01/03/ohr-pharmaceuticals-ohrp-stock-price-up-6-5.html.
About Ohr Pharmaceuticals
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.